Carlyle Group Co-Founder Joins Moderna Board

By Tamara Parker • Tuesday, July 23 08:12 • Permanent Link

David Rubenstein is set to join Moderna's board of directors on August 5, 2024, replacing retiring director Stephen Berenson. Rubenstein, the co-founder and co-chairman of the Carlyle Group, brings extensive multi-industry investor experience and global policy expertise to the board.

Upon Rubenstein's appointment, directors Robert Langer and Stephen Berenson will also retire from the board. Rubenstein will replace Berenson on the audit committee of the board. Both Langer and Berenson have agreed to continue providing advisory services to the company on key matters following their board retirement.

Rubenstein's appointment comes as Moderna is reaching its next stage of development as a commercial company with global reach. Moderna co-founder and chairman Noubar Afeyan expressed his excitement in welcoming Rubenstein to the board, highlighting his rich experience in investing and growing businesses across various industries and his global policy expertise.

Following Rubenstein's appointment, Moderna's nominating and corporate governance committee anticipates continuing to focus director recruitment efforts on individuals with scientific and innovation experience following Dr. Langer’s departure.

Rubenstein's background includes serving as the chairman of the Council on Foreign Relations and chairman of the Economic Club of Washington, D.C., in addition to his roles at the Carlyle Group and as the chairman, chief executive officer, and principal owner of the Baltimore Orioles of Major League Baseball.

Moderna, a leader in the creation of the field of mRNA medicine, has been working at the intersection of science, technology, and health for more than a decade. The company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Rubenstein's appointment is seen as crucial as Moderna continues its mission of delivering the greatest impact to people through mRNA medicines and as the company pursues its global growth strategy. The market has reacted to these announcements by moving the company's shares 1.1% to a price of $122.5. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.